KROS
Company Description
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the firm maintains its principal operations in Lexington, Massachusetts.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 244.06M | 3.55M | 151,000 | 0 | 20.10M | 0 | 10.00M | 10.00M |
| Net Income | 87.01M | (187.35M) | (152.99M) | (104.68M) | (58.74M) | (45.36M) | (12.34M) | (1.33M) |
| EPS | 2.34 | -5.00 | -5.20 | -4.15 | -2.52 | -2.93 | -1.39 | -0.15 |
| Free Cash Flow | 105.95M | (162.80M) | (126.97M) | (71.30M) | (63.17M) | (37.19M) | (16.27M) | 6.83M |
| FCF / Share | 2.85 | -4.35 | -4.31 | -2.82 | -2.71 | -2.40 | -1.83 | 0.77 |
| Operating CF | 107.50M | (160.87M) | (124.51M) | (70.06M) | (62.15M) | (36.89M) | (16.00M) | 7.04M |
| Total Assets | 338.02M | 615.89M | 370.02M | 306.78M | 255.25M | 269.44M | 10.96M | 27.41M |
| Total Debt | 16.88M | 18.86M | 14.44M | 13.27M | 1.09M | 899,000 | 1.27M | 788,000 |
| Cash & Equiv | 287.42M | 559.93M | 331.15M | 279.05M | 230.04M | 265.88M | 7.02M | 23.26M |
| Book Value | 303.13M | 571.55M | 332.21M | 277.42M | 243.17M | 261.72M | 495,000 | 12.76M |
| Return on Equity | 0.29 | -0.33 | -0.46 | -0.38 | -0.24 | -0.17 | -24.94 | -0.10 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 367,000 | 385,000 | 14.26M | 18.17M | 211.25M | 3.04M | 388,000 | 37,000 | 83,000 | 143,000 | 8,000 |
| Net Income | (28.71M) | (23.71M) | (23.46M) | (7.28M) | (30.70M) | 148.45M | (46.03M) | (52.96M) | (45.26M) | (43.11M) | (40.24M) | (39.44M) |
| EPS | -1.45 | -1.21 | -0.86 | -0.18 | -0.76 | 3.66 | -1.14 | -1.47 | -1.25 | -1.46 | -1.34 | -1.33 |
| Free Cash Flow | (20.58M) | (3.60M) | (27.43M) | 3.12M | (30.34M) | 160.61M | (46.30M) | (30.89M) | (40.11M) | (45.51M) | (26.00M) | (34.53M) |
| FCF / Share | -1.04 | -0.18 | -0.74 | 0.08 | -0.75 | 3.96 | -1.15 | -0.86 | -1.11 | -1.55 | -0.86 | -1.16 |
| Operating CF | (20.42M) | (3.53M) | (27.29M) | 3.25M | (29.62M) | 161.17M | (46.01M) | (30.50M) | (39.80M) | (44.56M) | (25.46M) | (33.98M) |
| Total Assets | 287.60M | 312.29M | 338.02M | 742.78M | 757.16M | 784.56M | 615.89M | 579.27M | 455.02M | 485.82M | 370.02M | 326.25M |
| Total Debt | 15.72M | 16.31M | 16.88M | 17.43M | 17.95M | 18.41M | 18.86M | 19.29M | 13.96M | 14.20M | 14.44M | 14.31M |
| Cash & Equiv | 257.61M | 281.50M | 287.42M | 693.47M | 690.22M | 720.54M | 559.93M | 530.68M | 405.86M | 442.44M | 331.15M | 287.89M |
| Book Value | 262.32M | 285.63M | 303.13M | 703.58M | 706.73M | 728.87M | 571.55M | 532.84M | 420.92M | 453.95M | 332.21M | 295.84M |
| Return on Equity | -0.11 | -0.08 | -0.08 | -0.01 | -0.04 | 0.20 | -0.08 | -0.10 | -0.11 | -0.09 | -0.12 | -0.13 |
